Xenografted Adult Human Mesenchymal Stem Cells Provide a Platform for Sustained Biological Pacemaker Function in Canine Heart

Background— Biological pacemaking has been performed with viral vectors, human embryonic stem cells, and adult human mesenchymal stem cells (hMSCs) as delivery systems. Only with human embryonic stem cells are data available regarding stability for >2 to 3 weeks, and here, immunosuppression has been used to facilitate survival of xenografts. The purpose of the present study was to determine whether hMSCs provide stable impulse initiation over 6 weeks without the use of immunosuppression, the “dose” of hMSCs that ensures function over this period, and the catecholamine responsiveness of hMSC-packaged pacemakers. Methods and Results— A full-length mHCN2 cDNA subcloned in a pIRES2-EGFP vector was electroporated into hMSCs. Transfection efficiency was estimated by GFP expression. IHCN2 was measured with patch clamp, and cells were administered into the left ventricular anterior wall of adult dogs in complete heart block and with backup electronic pacemakers. Studies encompassed 6 weeks. IHCN2 for all cells was 32.1±1.3 pA/pF (mean±SE) at −150 mV. Pacemaker function in intact dogs required 10 to 12 days to fully stabilize and persisted consistently through day 42 in dogs receiving ≥700 000 hMSCs (≈40% of which carried current). Rhythms were catecholamine responsive. Tissues from animals killed at 42 days manifested neither apoptosis nor humoral or cellular rejection. Conclusions— hMSCs provide a means for administering catecholamine-responsive biological pacemakers that function stably for 6 weeks and manifest no cellular or humoral rejection at that time. Cell doses >700 000 are sufficient for pacemaking when administered to left ventricular myocardium.

[1]  J. Hare,et al.  Emerging role for bone marrow derived mesenchymal stem cells in myocardial regenerative therapy , 2005, Basic Research in Cardiology.

[2]  M. Biel,et al.  A family of hyperpolarization-activated mammalian cation channels , 1998, Nature.

[3]  O. Koç,et al.  Human mesenchymal stem cells require monocyte-mediated activation to suppress alloreactive T cells. , 2005, Experimental hematology.

[4]  K. Chien.  Stem cells: Lost in translation , 2004, Nature.

[5]  E. Guinan,et al.  Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation , 2003, Transplantation.

[6]  Richard O Hynes,et al.  Guidelines for human embryonic stem cell research , 2005, Nature Biotechnology.

[7]  F. Welt,et al.  Cell therapy for acute myocardial infarction: curb your enthusiasm? , 2006, Circulation.

[8]  Eric R Kandel,et al.  Identification of a Gene Encoding a Hyperpolarization-Activated Pacemaker Channel of Brain , 1998, Cell.

[9]  Michael R Rosen,et al.  Expression and Function of a Biological Pacemaker in Canine Heart , 2003, Circulation.

[10]  Michael R Rosen,et al.  Biological Pacemaker Implanted in Canine Left Bundle Branch Provides Ventricular Escape Rhythms That Have Physiologically Acceptable Rates , 2004, Circulation.

[11]  W. Aird,et al.  Enhancement of murine cardiac chronotropy by the molecular transfer of the human beta2 adrenergic receptor cDNA. , 1998, The Journal of clinical investigation.

[12]  C. Lau,et al.  Bioartificial Sinus Node Constructed via In Vivo Gene Transfer of an Engineered Pacemaker HCN Channel Reduces the Dependence on Electronic Pacemaker in a Sick-Sinus Syndrome Model , 2006, Circulation.

[13]  Junyuan Gao,et al.  Human Mesenchymal Stem Cells as a Gene Delivery System to Create Cardiac Pacemakers , 2004, Circulation research.

[14]  C. Carlo-Stella,et al.  Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. , 2002, Blood.

[15]  M. O. Speidel,et al.  Metallurgy: High nickel release from 1- and 2-euro coins , 2002, Nature.

[16]  M. Josephson,et al.  Molecular enhancement of porcine cardiac chronotropy , 2001, Heart.

[17]  E. Azene,et al.  Gene Transfer of a Synthetic Pacemaker Channel Into the Heart: A Novel Strategy for Biological Pacing , 2006, Circulation.

[18]  M. Rosen,et al.  Wild-Type and Mutant HCN Channels in a Tandem Biological-Electronic Cardiac Pacemaker , 2006, Circulation.

[19]  Michael R Rosen,et al.  Genes, stem cells and biological pacemakers. , 2004, Cardiovascular research.

[20]  M. Rosen.  Are Stem Cells Drugs?: The Regulation of Stem Cell Research and Development , 2006, Circulation.

[21]  Rona Shofti,et al.  Electromechanical integration of cardiomyocytes derived from human embryonic stem cells , 2004, Nature Biotechnology.